Articles

Qualcomm’s stock isn’t the AI play that it was expected to be, analyst says

Shares of Qualcomm Inc. took a hit Tuesday after KeyBanc Capital dropped its longtime buy call, saying the semiconductor maker hasn’t been benefiting as expected from the artificial-intelligence boom and could start losing market share in the coming months.

‘DJT’ stock continues rally after Elon Musk joins Trump onstage in Pennsylvania

Shares of Trump Media & Technology Group are on pace to extend their winning streak to four days, their longest since a four-day streak that ended June 26.

U.S. trade deficit drops to 5-month low and could add to GDP. Exports hit record high.

The U.S. trade deficit sank almost 11% in August because of lower imports of oil and new cars, potentially giving a boost to the official measure of economic growth in the third quarter.

Brent falls below $80 as oil rally pauses, traders await Israeli response to Iranian missile attack

A rally in oil prices was taking a pause on Tuesday early morning as traders await Israel’s response Iran’s latest round of aggression.

OpenAI has been an asset for Microsoft. Now it could mean risk for the stock.

Oppenheimer downgraded Microsoft’s stock, warning that OpenAI losses could weigh on Microsoft earnings, all while AI revenue might trail expectations.

Retirees: You may not be getting your money’s worth from your adviser. How to know if it’s time to find a new one.

Advisers who excel in helping clients build their nest egg may be less skilled at addressing Social Security or drawdown strategies.

Want to be rich enough for the Forbes 400? The stock market won’t get you there.

Stock investing is how you keep wealth — not how you make it.

Small businesses have never been more uncertain, and it’s holding back spending, trade group says

Small businesses have never been more uncertain, and it’s impacting their spending plans, a leading trade group said Tuesday.

‘I want the calls and letters to stop’: My mother died owing $17,000 in credit-card debt. The creditors want their money. Will I have to sell her house?

“My mom passed away in May from Alzheimer’s. I was her primary caretaker.”

Sage Therapeutics’ stock slides after biotech says it will cease development of Alzheimer’s treatment

Sage Therapeutics Inc.’s stock tumbled 12.8% early Tuesday, after the company said a mid-stage trial of a treatment for mild cognitive impairment and mild dementia in Alzheimer’s disease failed to meet its main goal.

Excessive optimism is making the stock market vulnerable

There’s no way of knowing how long this game of brinkmanship can continue, but it’s a good bet that it will end badly.

After 70, is Social Security enough money to live on — or should I buy an annuity?

Guaranteed income can be a tricky concept in retirement planning.
1 783 784 785 786 787 2,383